Valeo Financial Advisors LLC Has $219,000 Stake in Baxter International Inc. $BAX

Valeo Financial Advisors LLC cut its holdings in Baxter International Inc. (NYSE:BAX) by 11.3% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 7,216 shares of the medical instruments supplier’s stock after selling 917 shares during the quarter. Valeo Financial Advisors LLC’s holdings in Baxter International were worth $219,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in BAX. Farther Finance Advisors LLC lifted its stake in shares of Baxter International by 84.4% in the 1st quarter. Farther Finance Advisors LLC now owns 7,487 shares of the medical instruments supplier’s stock valued at $255,000 after purchasing an additional 3,427 shares during the period. GAMMA Investing LLC increased its holdings in Baxter International by 248.3% in the first quarter. GAMMA Investing LLC now owns 11,326 shares of the medical instruments supplier’s stock valued at $388,000 after purchasing an additional 8,074 shares during the last quarter. SG Americas Securities LLC grew its position in shares of Baxter International by 352.6% during the 1st quarter. SG Americas Securities LLC now owns 74,094 shares of the medical instruments supplier’s stock worth $2,536,000 after buying an additional 57,723 shares during the period. Handelsbanken Fonder AB grew its position in shares of Baxter International by 8.0% during the 1st quarter. Handelsbanken Fonder AB now owns 314,320 shares of the medical instruments supplier’s stock worth $10,759,000 after buying an additional 23,218 shares during the period. Finally, Farmers & Merchants Investments Inc. grew its position in shares of Baxter International by 90.5% during the 1st quarter. Farmers & Merchants Investments Inc. now owns 15,755 shares of the medical instruments supplier’s stock worth $539,000 after buying an additional 7,485 shares during the period. Institutional investors and hedge funds own 90.19% of the company’s stock.

Analyst Upgrades and Downgrades

BAX has been the topic of several recent analyst reports. Evercore ISI reduced their price objective on shares of Baxter International from $33.00 to $31.00 and set an “outperform” rating on the stock in a research note on Tuesday. The Goldman Sachs Group lowered shares of Baxter International from a “buy” rating to a “neutral” rating and set a $25.00 target price on the stock. in a report on Friday, August 1st. Stifel Nicolaus reiterated a “hold” rating and issued a $25.00 target price (down from $36.00) on shares of Baxter International in a report on Monday, August 4th. Wall Street Zen cut shares of Baxter International from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Finally, Barclays lowered their price objective on shares of Baxter International from $41.00 to $36.00 and set an “overweight” rating for the company in a research report on Monday, August 4th. Three investment analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $28.89.

Baxter International Price Performance

Shares of NYSE BAX opened at $21.95 on Friday. The firm has a market cap of $11.27 billion, a PE ratio of -73.15, a PEG ratio of 0.74 and a beta of 0.58. The company has a current ratio of 2.30, a quick ratio of 1.49 and a debt-to-equity ratio of 1.30. Baxter International Inc. has a 1-year low of $21.33 and a 1-year high of $37.74. The company has a fifty day moving average price of $23.57 and a 200 day moving average price of $27.77.

Baxter International (NYSE:BAX) last issued its quarterly earnings results on Thursday, July 31st. The medical instruments supplier reported $0.59 EPS for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.01). The firm had revenue of $2.81 billion during the quarter, compared to the consensus estimate of $2.82 billion. Baxter International had a negative net margin of 1.42% and a positive return on equity of 16.96%. The business’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.68 earnings per share. Baxter International has set its Q3 2025 guidance at 0.580-0.620 EPS. FY 2025 guidance at 2.420-2.520 EPS. Research analysts predict that Baxter International Inc. will post 2.48 earnings per share for the current fiscal year.

Baxter International Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, October 1st. Stockholders of record on Friday, August 29th were paid a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a dividend yield of 3.1%. The ex-dividend date of this dividend was Friday, August 29th. Baxter International’s dividend payout ratio (DPR) is currently -226.67%.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.